Atogepant (Qulipta) for Migraine Prevention
Date: November 1, 2021
Issue #:
1636Summary:
Atogepant (Qulipta– Abbvie), an oral small-molecule
calcitonin gene-related peptide (CGRP) receptor
antagonist ( " gepant " ), has been approved by the
FDA for prevention of episodic migraine in adults. It
is the second oral CGRP receptor antagonist to be
approved in the US for this indication; the first was
rimegepant(Nurtec ODT), which is also approved
for acute treatment of migraine. Parenteral CGRP
monoclonal antibodies are approved for prevention
of migraine (see Table 3).
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: Aimovig Ajovy Amerge Atacand atogepant Beta blockers Botox Candesartan Cymbalta Depakote Divalproex sodium Duloxetine Effexor Emgality Epival eptinezumab erenumab fremanezumab Frova Frovatriptan galcanezumab Lopre Source Type: research
More News: Beta-Blockers | Botox | Cymbalta | Divalproex Sodium | Drugs & Pharmacology | Effexor | Genetics | Headache | Migraine | Sodium